These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24751518)

  • 21. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A.
    Coelmont L; Hanoulle X; Chatterji U; Berger C; Snoeck J; Bobardt M; Lim P; Vliegen I; Paeshuyse J; Vuagniaux G; Vandamme AM; Bartenschlager R; Gallay P; Lippens G; Neyts J
    PLoS One; 2010 Oct; 5(10):e13687. PubMed ID: 21060866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
    Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir.
    Garcia-Rivera JA; Bobardt M; Chatterji U; Hopkins S; Gregory MA; Wilkinson B; Lin K; Gallay PA
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5113-21. PubMed ID: 22802259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
    Qing J; Luo R; Wang Y; Nong J; Wu M; Shao Y; Tang R; Yu X; Yin Z; Sun Y
    Antiviral Res; 2016 Feb; 126():43-54. PubMed ID: 26724382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells.
    Ikeda M; Yi M; Li K; Lemon SM
    J Virol; 2002 Mar; 76(6):2997-3006. PubMed ID: 11861865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Specific inhibition of hepatitis C virus replication by cyclosporin A.
    Nakagawa M; Sakamoto N; Enomoto N; Tanabe Y; Kanazawa N; Koyama T; Kurosaki M; Maekawa S; Yamashiro T; Chen CH; Itsui Y; Kakinuma S; Watanabe M
    Biochem Biophys Res Commun; 2004 Jan; 313(1):42-7. PubMed ID: 14672695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.
    Aloia AL; Eyre NS; Black S; Bent SJ; Gaeguta A; Guo Z; Narayana SK; Chase R; Locarnini S; Carr JM; Howe JA; Beard MR
    Antivir Ther; 2015; 20(3):271-80. PubMed ID: 25222708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6.
    Imhof I; Simmonds P
    J Virol; 2010 May; 84(9):4597-610. PubMed ID: 20164226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database.
    Kliemann DA; Tovo CV; da Veiga AB; de Mattos AA; Wood C
    World J Gastroenterol; 2016 Oct; 22(40):8910-8917. PubMed ID: 27833382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro.
    Yang F; Robotham JM; Nelson HB; Irsigler A; Kenworthy R; Tang H
    J Virol; 2008 Jun; 82(11):5269-78. PubMed ID: 18385230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations in the hepatitis C virus polymerase that increase RNA binding can confer resistance to cyclosporine A.
    Liu Z; Robida JM; Chinnaswamy S; Yi G; Robotham JM; Nelson HB; Irsigler A; Kao CC; Tang H
    Hepatology; 2009 Jul; 50(1):25-33. PubMed ID: 19489073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
    Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
    Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations.
    Pawlotsky JM; Germanidis G; Neumann AU; Pellerin M; Frainais PO; Dhumeaux D
    J Virol; 1998 Apr; 72(4):2795-805. PubMed ID: 9525599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins.
    Nakagawa M; Sakamoto N; Tanabe Y; Koyama T; Itsui Y; Takeda Y; Chen CH; Kakinuma S; Oooka S; Maekawa S; Enomoto N; Watanabe M
    Gastroenterology; 2005 Sep; 129(3):1031-41. PubMed ID: 16143140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
    He Y; King MS; Kempf DJ; Lu L; Lim HB; Krishnan P; Kati W; Middleton T; Molla A
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1101-10. PubMed ID: 18086851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A.
    Ciesek S; Steinmann E; Wedemeyer H; Manns MP; Neyts J; Tautz N; Madan V; Bartenschlager R; von Hahn T; Pietschmann T
    Hepatology; 2009 Nov; 50(5):1638-45. PubMed ID: 19821520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adaptive Mutations in Replicase Transmembrane Subunits Can Counteract Inhibition of Equine Arteritis Virus RNA Synthesis by Cyclophilin Inhibitors.
    de Wilde AH; Boomaars-van der Zanden AL; de Jong AWM; Bárcena M; Snijder EJ; Posthuma CC
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31243130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon.
    Ma S; Boerner JE; TiongYip C; Weidmann B; Ryder NS; Cooreman MP; Lin K
    Antimicrob Agents Chemother; 2006 Sep; 50(9):2976-82. PubMed ID: 16940091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems.
    Lin HM; Wang JC; Hu HS; Wu PS; Wang WH; Wu SY; Yang CC; Yeh TK; Hsu TA; Jiaang WT; Chao YS; Chern JH; Yueh A
    Antimicrob Agents Chemother; 2013 Feb; 57(2):723-33. PubMed ID: 23165461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of AP80978, a novel small-molecule inhibitor of hepatitis C virus replication that targets NS4B.
    Dufner-Beattie J; O'Guin A; O'Guin S; Briley A; Wang B; Balsarotti J; Roth R; Starkey G; Slomczynska U; Noueiry A; Olivo PD; Rice CM
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3399-410. PubMed ID: 24709254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.